Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Xu-Bin Zheng"'
Autor:
Xu-Bin Zheng, Vinod K. Diwan, Qi Zhao, Yi Hu, Judith Bruchfeld, Wei-Li Jiang, Sven Hoffner, Biao Xu
Publikováno v:
Infectious Diseases of Poverty, Vol 9, Iss 1, Pp 1-9 (2020)
Abstract Background China incurs an extremely low treatment coverage of multidrug-resistant tuberculosis (MDR-TB). This study aimed to understand the experience of MDR-TB patients on quality of health care, and the clinical impact through an up to si
Externí odkaz:
https://doaj.org/article/7bf418631fe84739a8a42008e9ae4830
Autor:
Bing-Ying Li, Wen-Pei Shi, Chang-Ming Zhou, Qi Zhao, Vinod K Diwan, Xu-Bin Zheng, Yang Li, Sven Hoffner, Biao Xu
Publikováno v:
Infectious Diseases of Poverty, Vol 9, Iss 1, Pp 1-8 (2020)
Abstract Background Multidrug-resistant tuberculosis (MDR-TB) is on the rise in China. This study used a dynamic Markov model to predict the longitudinal trends of MDR-TB in China by 2050 and to assess the effects of alternative control measures. Met
Externí odkaz:
https://doaj.org/article/22843631b534476caedb573310f7d4ce
Autor:
Hong Ren, Abram L Wagner, Jia-Yu Xie, Kai-Yun Chen, Yi-Han Lu, Xu-Bin Zheng, Tao Huang, Matthew L Boulton, Xiang-Xiang Chen
Publikováno v:
Health Services Insights, Vol 12 (2019)
Low- and middle-income countries receive limited guidance from external entities about how to introduce vaccines. This is especially true for the Hepatitis E (HepE) vaccine, which is currently only commercially available in China. The aims of this qu
Externí odkaz:
https://doaj.org/article/c98e947d68fd44228201e9aa6eedc195
Autor:
Jia-Yu Xie, Xiangxiang Chen, Yihan Lu, Hong Ren, Matthew L. Boulton, Abram L. Wagner, Xu-Bin Zheng, Kai-Yun Chen
Publikováno v:
Vaccine. 37:6566-6572
Background A hepatitis E (HepE) vaccine was developed and released in China in 2011. Uptake is currently very limited. The aims of this study were to characterize what public health professionals thought about promoting the HepE vaccine in Shanghai,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed417b4f01abeca74b35cf59f6072717
https://doi.org/10.1016/j.vaccine.2019.07.067
https://doi.org/10.1016/j.vaccine.2019.07.067
Autor:
Yihan Lu, Abram L. Wagner, Xu-Bin Zheng, Kai-Yun Chen, Jia-Yu Xie, Xiangxiang Chen, Tao Huang, Hong Ren, Matthew L. Boulton
Publikováno v:
Health Services Insights, Vol 12 (2019)
Health Services Insights
Health Services Insights
Low- and middle-income countries receive limited guidance from external entities about how to introduce vaccines. This is especially true for the Hepatitis E (HepE) vaccine, which is currently only commercially available in China. The aims of this qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11cab3bf62a1b5e808fb9273cdd44b36
https://doaj.org/article/c98e947d68fd44228201e9aa6eedc195
https://doaj.org/article/c98e947d68fd44228201e9aa6eedc195